Effects of Pilocarpine Hydrochloride and Cevimeline on Submandibular/ Sublingual Salivation in Rat Xerostomia Model Produced by X-Ray Irradiation

Summary The present study was performed to assess the effects of pilocarpine hydrochloride ((3S,4R)-3-ethyl-dihydro-4-[(1-methyl-1H-imidazole-5-yl)methyl]-2(3H)-furanone monohydrochloride, CAS54-71-7) and cevimeline ((±)-cis-2-methylspiro[1,3-oxathiolane-5,3’-quinuclidine] hydrochloride, hemihydrate, CAS 153504-70-2), muscarinic receptor agonists, on salivary secretion from the submandibular/sublingual (SM/ SL) glands in normal rats and in rats with xerostomia induced by X-ray (15 Gy) irradiation. To clarify their pharmacological safety profiles, the two drugs were further compared with regard to subtype selectivity for muscarinic receptors (M1, M2, and M3) and central nervous, respiratory, and cardiovascular effects. Pilocarpine hydrochloride (0.1−0.8 mg/kg i.d.) and cevimeline (3−30 mg/kg i.d.) dose-dependently increased salivary flow rate and total salivary volume in a 120-min period from SM/SL glands in both normal and irradiated rats, the minimum effective doses for their sialagogic effects being 0.2 and 10 mg/kg, respectively. Both drugs also increased protein output from SM/SL glands to a degree that depended on the increase in salivary volume in normal and irradiated rats. In a binding study using radiolabeled antagonists, neither pilocarpine hydrochloride nor cevimeline displayed subtype selectivity for muscarinic receptors, indicating non-selective muscarinic agonism. Effects on the central nervous system (CNS) were assessed by monitoring changes in body temperature in conscious normal rats. Pilocarpine hydrochloride (0.4−4 mg/kg p.o.) had no effect on body temperature, but cevimeline (30 and 100 mg/kg p.o.) caused a significant hypothermia. In terms of respiratory and cardiovascular effects in anesthetized normal rats, there was no clear difference in safety margin between pilocarpine hydrochloride and cevimeline, both drugs inducing significant changes in respiratory rate, heart rate, and blood pressure at doses close to those inducing sialagogic effects. These results suggest that pilocarpine hydrochloride could be used as a sialagogic drug for postirradiation-induced xerostomia with fewer adverse effects on the CNS.

[1]  Christian C Felder,et al.  Evaluation of muscarinic agonist-induced analgesia in muscarinic acetylcholine receptor knockout mice. , 2002, Molecular pharmacology.

[2]  R. Eglen,et al.  Therapeutic opportunities from muscarinic receptor research. , 2001, Trends in pharmacological sciences.

[3]  K. Kohsaka,et al.  Pharmacokinetics of SNI-2011 (1) : Absorption, Distribution, Metabolism and Excretion of 14C-SNI-2011 in Rats , 2001 .

[4]  M. Sugimoto,et al.  Activation of cerebral function by CS-932, a functionally selective M1 partial agonist: neurochemical characterization and pharmacological studies. , 2000, Japanese journal of pharmacology.

[5]  Y. Iga,et al.  (+/-)-cis-2-methylspiro[1,3-oxathiolane-5,3'-quinuclidine] hydrochloride, hemihydrate (SNI-2011, cevimeline hydrochloride) induces saliva and tear secretions in rats and mice: the role of muscarinic acetylcholine receptors. , 1998, Japanese journal of pharmacology.

[6]  T. Tomizuka,et al.  Long-lasting salivation induced by a novel muscarinic receptor agonist SNI-2011 in rats and dogs. , 1997, European journal of pharmacology.

[7]  Y. Marmary,et al.  Irradiation-induced damage to the salivary glands: the role of redox-active iron and copper. , 1997, Radiation research.

[8]  M. Katagiri,et al.  Salivary secretion and histopathological effects after single administration of the muscarinic agonist SNI-2011 in MRL/lpr mice. , 1994, Archives internationales de pharmacodynamie et de therapie.

[9]  J. Johnson,et al.  Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer. , 1993, The New England journal of medicine.

[10]  T. Masuhara,et al.  Subtypes of the muscarine receptors that are involved in pilocarpine-induced secretion of saliva from rat sublingual glands , 1992 .

[11]  R. Henriksson,et al.  Parotid gland function during and following radiotherapy of malignancies in the head and neck. A consecutive study of salivary flow and patient discomfort. , 1992, European journal of cancer.

[12]  B. Baum,et al.  Evidence that M3 muscarinic receptors in rat parotid gland couple to two second messenger systems. , 1991, The American journal of physiology.

[13]  A. Vissink,et al.  Acute irradiation effects on morphology and function of rat submandibular glands. , 1991, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[14]  M. Terai,et al.  Pharmacological studies on novel muscarinic agonists, 1-oxa-8-azaspiro[4.5]decane derivatives, YM796 and YM954. , 1990, European journal of pharmacology.

[15]  T. Daniels,et al.  Effectiveness of pilocarpine in postradiation xerostomia , 1987, Cancer.

[16]  W. E. Wright,et al.  Therapy-induced dysfunction of salivary glands: implications for oral health. , 1985, Special care in dentistry : official publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry.

[17]  L. Tabak,et al.  Role of salivary mucins in the protection of the oral cavity. , 1982, Journal of oral pathology.

[18]  J. B. Drane,et al.  Prevention of Xerostomia-Related Dental Caries in Irradiated Cancer Patients , 1977, Journal of dental research.

[19]  C. Dawes Rhythms in salivary flow rate and composition. , 1974, International journal of chronobiology.